BiPar Sciences Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $539M

BiPar Sciences General Information

Description

Developer of tumor-selective drugs designed to target multiple cancer types including therapy-resistant and difficult-to-treat cancers. The company offers a poly ribose polymerase inhibitor for metastatic triple-negative breast cancer, ovarian cancer, and other malignancies, a follow-on inhibitor candidate for pancreatic cancer, and an iodothyronine program with anti-tubulin properties, thereby enabling healthcare providers to enhance the anti-tumor effects of chemotherapy.

Contact Information

Website
www.biparsciences.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 400 Oyster Point Boulevard
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Acquirer
Sanofi
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 400 Oyster Point Boulevard
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BiPar Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 15-Apr-2009 $539M Completed Generating Revenue
5. Later Stage VC (Series C) 12-Jan-2009 Completed Generating Revenue
4. Later Stage VC (Series B1) 30-Dec-2008 Completed Generating Revenue
3. Later Stage VC (Series B) 26-Feb-2007 Completed Generating Revenue
2. Debt - General 14-Jun-2006 $5M $18M Completed Startup
1. Early Stage VC (Series A) 20-Dec-2004 $13M $13M Completed Startup
To view BiPar Sciences’s complete valuation and funding history, request access »

BiPar Sciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B1
Series B
Series A 29,893,629 $0.001000 $0.03 $0.44 $0.44 1x $0.44 21.71%
To view BiPar Sciences’s complete cap table history, request access »

BiPar Sciences Patents

  • 104

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • Pending

  • Expiring in next 12 mo

BiPar Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120245117-A1 Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin Inactive 04-Mar-2011
CA-2805774-A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents Inactive 19-Jul-2010
EP-2595618-A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents Inactive 19-Jul-2010
EP-2595619-A1 Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan Inactive 19-Jul-2010
AU-2011282223-A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents Inactive 19-Jul-2010 A61K31/4745
To view BiPar Sciences’s complete patent history, request access »

BiPar Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiPar Sciences Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asset Management Ventures Venture Capital Minority
Canaan Partners Venture Capital Minority
Cercano Management PE/Buyout Minority
Domain Associates Venture Capital Minority
Lighthouse Capital Partners Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

BiPar Sciences FAQs

  • When was BiPar Sciences founded?

    BiPar Sciences was founded in 2002.

  • Where is BiPar Sciences headquartered?

    BiPar Sciences is headquartered in South San Francisco, CA.

  • What is the size of BiPar Sciences?

    BiPar Sciences has 20 total employees.

  • What industry is BiPar Sciences in?

    BiPar Sciences’s primary industry is Drug Discovery.

  • Is BiPar Sciences a private or public company?

    BiPar Sciences is a Private company.

  • What is the current valuation of BiPar Sciences?

    The current valuation of BiPar Sciences is .

  • What is BiPar Sciences’s current revenue?

    The current revenue for BiPar Sciences is .

  • How much funding has BiPar Sciences raised over time?

    BiPar Sciences has raised $78M.

  • Who are BiPar Sciences’s investors?

    Asset Management Ventures, Canaan Partners, Cercano Management, Domain Associates, and Lighthouse Capital Partners are 5 of 12 investors who have invested in BiPar Sciences.

  • When was BiPar Sciences acquired?

    BiPar Sciences was acquired on 15-Apr-2009.

  • Who acquired BiPar Sciences?

    BiPar Sciences was acquired by Sanofi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »